Principal Financial Group
CSTL icon

Principal Financial Group’s Castle Biosciences CSTL Stock Holding History

Principal Financial Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.2M Sell
1,726,648
-43,229
-2% -$963K 0.02% 596
2026
Q1 		$43.5M Sell
1,769,877
-37,767
-2% -$1.24M 0.02% 529
2025
Q4 		$70.3M Buy
1,807,644
+13,289
+0.7% +$428K 0.04% 366
2025
Q3 		$40.9M Sell
1,794,355
-4,619
-0.3% -$93.8K 0.02% 533
2025
Q2 		$36.7M Buy
1,798,974
+331,101
+23% +$6.13M 0.02% 560
2025
Q1 		$29.4M Buy
1,467,873
+32,208
+2% +$797K 0.02% 629
2024
Q4 		$38.3M Sell
1,435,665
-102,855
-7% -$3.13M 0.02% 547
2024
Q3 		$43.9M Buy
1,538,520
+40,377
+3% +$1.03M 0.02% 508
2024
Q2 		$32.6M Sell
1,498,143
-34,329
-2% -$765K 0.02% 607
2024
Q1 		$33.9M Sell
1,532,472
-53,201
-3% -$1.16M 0.02% 623
2023
Q4 		$34.2M Buy
1,585,673
+103,503
+7% +$1.82M 0.02% 581
2023
Q3 		$25M Buy
1,482,170
+122,169
+9% +$2.14M 0.02% 690
2023
Q2 		$18.7M Buy
1,360,001
+72,854
+6% +$1.48M 0.01% 889
2023
Q1 		$29.2M Buy
1,287,147
+376,327
+41% +$9.19M 0.02% 634
2022
Q4 		$21.4M Buy
910,820
+475,080
+109% +$11M 0.02% 781
2022
Q3 		$11.4M Buy
435,740
+186,064
+75% +$5.22M 0.01% 1116
2022
Q2 		$5.48M Buy
249,676
+72,226
+41% +$1.68M ﹤0.01% 1522
2022
Q1 		$7.96M Sell
177,450
-5,217
-3% -$216K 0.01% 1496
2021
Q4 		$7.83M Buy
182,667
+12,851
+8% +$672K ﹤0.01% 1513
2021
Q3 		$11.3M Buy
169,816
+989
+0.6% +$69.6K 0.01% 1343
2021
Q2 		$12.4M Buy
168,827
+80,263
+91% +$5.3M 0.01% 1321
2021
Q1 		$6.06M Buy
88,564
+10,212
+13% +$768K ﹤0.01% 1605
2020
Q4 		$5.26M Buy
78,352
+50,052
+177% +$2.71M ﹤0.01% 1545
2020
Q3 		$1.46M Buy
28,300
+1,800
+7% +$80.1K ﹤0.01% 1801
2020
Q2 		$999K Buy
+26,500
New +$905K ﹤0.01% 1831

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Principal Financial Group's CSTL Position: Q2 2026 in Review

Principal Financial Group reduced its Castle Biosciences (CSTL) stake by 2.4% in Q2 2026, selling an estimated $963K and leaving 1,726,648 shares worth $41.2M. The position accounts for 0.02% of the portfolio, ranked #596.

Principal Financial Group first reported a position in CSTL in Q2 2020 and has held it in 25 quarters since. The position peaked at $70.3M in Q4 2025. 176 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Principal Financial Group held 1,726,648 shares of Castle Biosciences worth $41.2M as of Q2 2026.
  • Principal Financial Group sold 43,229 Castle Biosciences shares in Q2 2026, an estimated $963K.
  • Castle Biosciences made up 0.02% of Principal Financial Group's portfolio in Q2 2026, its #596 holding.
  • Principal Financial Group first reported a position in Castle Biosciences in Q2 2020 and has held it in 25 quarters since.
  • Principal Financial Group's Castle Biosciences position peaked at $70.3M in Q4 2025.
  • 176 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.